Kenvue's shares climbed 6% on Tuesday, rebounding from a record low hit in the previous session, as analysts pointed to the lack of new scientific evidence from the White House to support President Donald Trump linking the drugmaker's popular pain reliever Tylenol to autism.

Doctors in the US will soon be advised not to prescribe the pain reliever Tylenol to pregnant women, US President Donald Trump said, citing a disputed link between the drug and autism.

His administration had just highlighted a link between the use of a common pain-relieving drug Tylenol (acetaminophen)—also known as paracetamol—and autism and ADHD. Mr Trump is certain that the drug is dangerous for children and has few real benefits.

The work of epidemiologist Ann Bauer and her co-authors was cited by President Trump in remarks linking Tylenol or acetaminophen with an increased incidence of autism.

Autism's answer may not be so simple: Decades of medical and scientific consensus indicate there is no singular source to autism, including medication, that can be attributed to the condition, and that it is likely the result of multiple contributing factors like genetics and environment.

Kenvnue stock rallied on Tuesday off a record low, after a White House press conference didn’t offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to autism.

Kenvue, a two-year-old spinoff from Johnson & Johnson, is confronting a public-relations nightmare as President Trump and others suggest unproven links between the pain reliever and autism.

Don’t take Tylenol, don’t take it,” Trump said. “Fight like hell not to take it.” He repeated the “don’t take Tylenol” refrain or slight variations of that at least 10 times during a wide-ranging White House briefing that also touched on vaccines and obesity medications,